The promise and perils of HDAC inhibitors in neurodegeneration

Alessandro Didonna, Puneet Opal*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

89 Scopus citations


Histone deacetylases (HDACs) represent emerging therapeutic targets in the context of neurodegeneration. Indeed, pharmacologic inhibition of HDACs activity in the nervous system has shown beneficial effects in several preclinical models of neurological disorders. However, the translation of such therapeutic approach to clinics has been only marginally successful, mainly due to our still limited knowledge about HDACs physiological role particularly in neurons. Here, we review the potential benefits along with the risks of targeting HDACs in light of what we currently know about HDAC activity in the brain.

Original languageEnglish (US)
Pages (from-to)79-101
Number of pages23
JournalAnnals of clinical and translational neurology
Issue number1
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Clinical Neurology
  • General Neuroscience


Dive into the research topics of 'The promise and perils of HDAC inhibitors in neurodegeneration'. Together they form a unique fingerprint.

Cite this